Stephen Mayo
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Allogene CFO Departure Comes Amid CAR-T Sector Safety Concerns. Allogene announced that Chief Financial Officer Geoffrey Parker will retire effective November 6, marking a leadership transition at a challenging time for the company. The timing coincides with broader scrutiny of CAR-T therapies for autoimmune conditions after competing trials from Novartis and Bristol Myers were paused over safety concerns. On the clinical front, the company indicated that if its minimal residual disease data holds, it could represent a significant shift in its business outlook. The stock has traded within a $1.04 to $4.46 range over the past year.
Transaction History
| SRPT | ▲ Buy | Grant | 16,875 | — | 6/4/2026 | View on chart |
| SRPT | ▼ Sell | Open Market | 7,239 | $123K | 3/12/2026 | View on chart |
| SRPT | ▲ Buy | Grant | 2,383 | — | 3/10/2025 | View on chart |
| SRPT | ▼ Sell | Open Market | 3,135 | $385K | 3/5/2024 | View on chart |
| SRPT | ▲ Buy | Grant | 1,846 | $0 | 3/1/2024 | View on chart |
| ALLO | ▼ Sell | Open Market | 10,000 | $43K | 8/7/2023 | View on chart |
| SRPT | ▲ Buy | Grant | 1,523 | $0 | 3/6/2023 | View on chart |
| SRPT | ▼ Sell | Open Market | 858 | $94K | 11/17/2022 | View on chart |
| ALLO | ▲ Buy | Grant | 35,328 | $0 | 7/8/2022 | View on chart |
| SRPT | ▲ Buy | Grant | 2,953 | $0 | 3/7/2022 | View on chart |
| SRPT | ▲ Buy | Grant | 4,292 | $0 | 11/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Sarepta settles patent dispute with REGENXBIO for $39M
Sarepta Therapeutics has resolved all ongoing patent litigation with REGENXBIO through a $39 million settlement. The agreement includes a clause where REGENXBIO agrees not to sue Sarepta over existing Elevidys or AAVrh74-based capsids. This development removes a significant legal uncertainty surrounding the company's key product, allowing Sarepta to focus on presenting new neuromuscular data at an upcoming scientific meeting.
Sarepta settles patent dispute with REGENXBIO for $39M. Sarepta Therapeutics has resolved all ongoing patent litigation with REGENXBIO through a $39 million settlement. The agreement includes a clause where REGENXBIO agrees not to sue Sarepta over existing Elevidys or AAVrh74-based capsids. This development removes a significant legal uncertainty surrounding the company's key product, allowing Sarepta to focus on presenting new neuromuscular data at an upcoming scientific meeting.